Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday Nov 20, 2009

DrStockPick.com Stock Report!

**************************************************************

Consorteum Holdings Inc. (OTCBB: CSRH) launched its consumer stored value rebate card. The consumer rebate card program will offer manufacturers and retailers a new way to process mail-in rebates that ensures increased customer loyalty and decreased overhead costs. Consorteum will work directly with manufactures and retailers to reduce the administration costs associated with mail-in rebate programs while providing a new way to increase consumer awareness. Additional revenue and cost-saving opportunities will be available to all parties through unspent funds

...

MivInvestments Inc. has initiated an independent bullish technical trading alert for 11/20/09 on Echo Therapeutics, Inc. (OTC:ECTE.OB). Shares of the company finished the day at $1.35, up 8.15% from the opening bell on heavy buying pressure. The excitement was due to the announcement on positive results of a clinical study testing symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes. Despite the fact that there has been a recent common shares financing scheduled, companies usually take their time and let the price consolidate before engaging in these activities, thus a short-term buy could be a smart investment. Towards the end of this alert a technical analysis will also be issued.

According to the ADA, the cost of diabetes care in the United States in 2007 was more than $174 billion, including $116 billion in excess medical expenditures attributed to diabetes and

...

NXT Nutritionals Holdings Inc. is a developer and marketer of proprietary, patent-pending, healthy alternative sweeteners, food and beverage products. The common ingredient for all of the company’s products is its SUSTA natural sweetener – a minimal calorie, all-natural, nutritional sweetening system.

The company announced today that Dr. James R. Gavin III has been named to their medical advisory board. Dr. Gavin currently serves as clinical professor of medicine at both Emory University School of Medicine in Atlanta, Georgia and the Indiana University School of Medicine in Indianapolis, Indiana. He also is the CEO and chief medical officer of Healing Our Village Inc.

Dr. Gavin is expected to provide his expertise on how NXT Nutritionals’ SUSTA natural sweetener product can help people with diabetes. He is a past president of the American Diabetes Association and was voted clinician of the year in diabetes by the ADA in 1991. He is also the recipient

...

Home Diagnostics Inc. (HDIX) recently announced that it has received the honor of being added to the Russell 3000, Russell 2000 and Russell Global Indexes. As the name suggests, these indices rank top U.S. companies by market capitalization. The indices are used by investors, primarily institutions, as benchmarks for both passive and active investment strategies.

Home Diagnostics is a developer, manufacturer and marketer of blood glucose monitoring systems and disposable supplies for people with diabetes. The company sells its products through food and drug retailers, mass merchandisers, distributors, mail service providers and third-party payors in the United States and Latin America, the United Kingdom, Germany, Australia and China.

Home Diagnostics addresses a large and expanding diabetes market ($7.0 billion, according to our estimates). Diabetes is a chronic life-threatening disease that is incurable. The goal of intensive blood glucose management is to achieve near-normal blood glucose levels without

...

For Immediate Release

Chicago, IL - June 24, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tiffany (TIF), Big Lots (BIG), Family Dollar (FDO), Isis Pharmaceuticals (ISIS) and OncoGenex (OGXI).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday's Analyst Blog:

Long-Term Job Stagnation

The two major forces behind the secular slowdown in job creation have been automation and globalization (off-shoring). It would not be particularly wise to reverse job losses coming from automation, since technology is the source of productivity growth and ultimately higher standards of living.

...

Vivus, Inc. (VVUS) was very active at this year's American Diabetes Association (ADA) meeting held in early June 2009. The company presented impressive data on Qnexa that demonstrates both the significant weight loss and glycemic control benefits of the drug.Glycemic analysis of the phase III 28-week EQUATE (OB-301) data, which was originally released in December 2008, demonstrated that patients on the full dose of Qnexa (15mg phentermine / 92 mg topiramate controlled release) showed a reduction in HbA1c by a placebo-adjusted amount of 0.11%, while losing approximately 9.2% (19.8 lbs) of their body weight. Patients on the mid-dose of Qnexa (7.5mg phentermine / 46 mg topiramate controlled release) showed a reduction in HbA1c by a placebo-adjusted amount of 0.10%, while losing approximately 8.5% (18.2 lbs) of their body weight.Long-term data from the phase II 56-week DM-230 trial demonstrated that patients on the full dose ...

For Immediate Release

Chicago, IL - June 9, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amylin Pharmaceuticals (AMLN), Merck (MRK), Glaxo (GSK), Bristol (BMY) and Eli Lilly (LLY).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Monday's Analyst Blog:

Amylin Update Post ADA Meeting

This past weekend, Amylin Pharmaceuticals (AMLN) presented several abstracts and oral presentations at the American Diabetes Association (ADA) meeting in New Orleans. At the meeting, Amylin presented long-term follow-up data from the 74-week open label portion of the DURATION-1 program that demonstrated

...

Liberator Medical Holdings, Inc. announced this morning that it has formed a new division to meet the educational needs of millions in the United States. The new Diabetes Self-Management Program is being led by industry veteran Evelyn P. Schumacher, MS, RD, CDE, who has agreed to serve as Vice-President of the new division, Liberator Health and Education Services, Inc., a wholly owned subsidiary of Liberator Medical Holdings, Inc.

Ms. Schumacher has more than ten years of experience in diabetes education as a registered dietitian and a certified diabetes educator. Ms. Schumacher has served as Program Coordinator/Educator for Shands Jacksonville and also served as Diabetes Educator for Baker, Nassau and Duval Counties in Florida. Additionally, Ms. Schumacher served as a speaker for GlaxoSmithKline, Bayer Healthcare, Novartis, Eli Lilly and Co, and Sanofi-Aventis. Currently, she serves as President of the Jacksonville Association of Diabetes Educators and Chair of the American Association of

...

Highlights include Arena Pharmaceuticals, Inc. (ARNA), Vivus, Inc. (VVUS), Orexigen Therapeutics, Inc. (OREX) Merck & Co., Inc. (MRK) and Johnson & Johnson (JNJ.Arena's Lorcaserin Approvable, But No BlockbusterOn March 30, 2009, Arena Pharmaceuticals (ARNA) released the much-anticipated results of the 2-year BLOOM clinical trial studying 10mg BID lorcaserin vs. placebo. Full data will be presented at the American Diabetes Association (ADA) meeting in early June 2009.The results are mixed, in our view. To put things in perspective, we will analyze the data stand-alone based on the FDA's guidelines for approvability. FDA guidelines say that one of the below two endpoints must be met:1) The drug must demonstrate a mean categorical weight loss of 5% in greater than 35% of the study participants, and these results must be twice that of the placebo group.The BLOOM ...